Having trouble accessing articles? Reset your cache.

Disparities in FDA decisions on Sarepta DMD therapy raise questions about integrity of review process

FDA letters, written by different officials, point to Exondys’ controversial approval as justification for decisions

Documents released Wednesday by FDA reveal unexplained discrepancies between an August complete response letter for Vyondys 53 golodirsen and December’s surprising accelerated approval of the therapy. The differences between FDA’s skepticism about the development program and its decision to approve the Sarepta Therapeutics Inc. (NASDAQ:SRPT) drug raise questions about the integrity of the agency’s review process.

Following the complete response letter (CRL) on Aug. 19, Sarepta submitted

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers